**CONSORT CHECKLIST – extension for cluster designs**

| **Section/topic and item No** | **Standard checklist item** | **Extension for cluster designs** | **Section** |
| --- | --- | --- | --- |
| **Title and abstract** |
| 1a | Identification as a randomised trial in the title | Identification as a cluster randomised trial in the title | Title/abstract |
| 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)11 12 | See next table | Abstract |
| **Introduction** |
| Background and objectives: |  |  |  |
|  2a | Scientific background and explanation of rationale | Rationale for using a cluster design | Background |
|  2b | Specific objectives or hypotheses | Whether objectives pertain to the cluster level, the individual participant level, or both | Background |
| **Methods** |
| Trial design: |  |  |  |
|  3a | Description of trial design (such as parallel, factorial) including allocation ratio | Definition of cluster and description of how the design features apply to the clusters | Materials and methods (Trial design) |
|  3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons |  | Materials and methods (Trial design) |
| Participants: |  |  |  |
|  4a | Eligibility criteria for participants | Eligibility criteria for clusters | Materials and methods (Setting, eligibility and recruitment) |
|  4b | Settings and locations where the data were collected |  | Materials and methods (Setting, eligibility and recruitment) |
| Interventions: |  |  |  |
|  5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | Whether interventions pertain to the cluster level, the individual participant level, or both | Materials and methods (Intervention) |
| Outcomes: |  |  |  |
|  6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | Whether outcome measures pertain to the cluster level, the individual participant level, or both | Materials and methods (Outcomes) |
|  6b | Any changes to trial outcomes after the trial commenced, with reasons |  | n/a |
| Sample size: |  |  |  |
|  7a | How sample size was determined | Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intra-cluster correlation (ICC or *k*), and an indication of its uncertainty | Materials and methods (Sample size estimate) |
|  7b | When applicable, explanation of any interim analyses and stopping guidelines |  | n/a |
| **Randomisation** |
| Sequence generation: |  |  |  |
|  8a | Method used to generate the random allocation sequence |  | Materials and methods (Randomisation and allocation) |
|  8b | Type of randomisation; details of any restriction (such as blocking and block size) | Details of stratification or matching if used | Materials and methods (Randomisation and allocation) |
| Allocation concealment mechanism: |  |  |  |
| 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level, or both | Materials and methods (Randomisation and allocation) |
| Implementation: |  |  |  |
|  10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | Replaced by 10a, 10b, and 10c |  |
|  10a |  | Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions | Materials and methods (Randomisation and allocation) |
|  10b |  | Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete enumeration, random sampling) | Materials and methods (Randomisation and allocation) |
|  10c |  | From whom consent was sought (representatives of the cluster, or individual cluster members, or both) and whether consent was sought before or after randomisation | Materials and methods (Ethics; Setting, eligibility and recruitment) |
| Blinding: |  |  |  |
|  11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how |  | Materials and methods (Blinding) |
|  11b | If relevant, description of the similarity of interventions |  | n/a |
| Statistical methods: |  |  |  |
|  12a | Statistical methods used to compare groups for primary and secondary outcomes | How clustering was taken into account | Materials and methods (Sample size estimate) |
|  12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses |  | Materials and methods (Statistical analyses) |
| **Results** |
| Participant flow (a diagram is strongly recommended): |  |  |  |
|  13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome | For each group, the numbers of clusters that were randomly assigned, received intended treatment, and were analysed for the primary outcome | Fig 1 |
|  13b | For each group, losses and exclusions after randomisation, together with reasons | For each group, losses and exclusions for both clusters and individual cluster members | Fig 1 |
| Recruitment: |  |  |  |
|  14a | Dates defining the periods of recruitment and follow-up |  | Materials and methods (Setting, eligibility and recruitment) |
|  14b | Why the trial ended or was stopped |  | Materials and methods (Setting, eligibility and recruitment) |
| Baseline data: |  |  |  |
|  15 | A table showing baseline demographic and clinical characteristics for each group | Baseline characteristics for the individual and cluster levels as applicable for each group | Table 1 |
| Numbers analysed: |  |  |  |
|  16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | For each group, number of clusters included in each analysis | Fig 1; Results |
| Outcomes and estimation: |  |  |  |
|  17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or *k*) for each primary outcome | Results |
|  17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended |  | n/a |
| Ancillary analyses: |  |  |  |
|  18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing prespecified from exploratory |  | n/a |
| Harms: |  |  |  |
|  19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms106) |  | n/a |
| **Discussion** |
| Limitations: |  |  |  |
|  20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses |  | Discussion (Strengths and limitations) |
| Generalisability: |  |  |  |
|  21 | Generalisability (external validity, applicability) of the trial findings | Generalisability to clusters and/or individual participants (as relevant) | Discussion (Strengths and limitations) |
| Interpretation: |  |  |  |
|  22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence |  | Discussion  |
| **Other information** |
| Registration: |  |  |  |
|  23 | Registration number and name of trial registry |  | Abstract; Materials and methods (Ethics statement) |
| Protocol: |  |  |  |
|  24 | Where the full trial protocol can be accessed, if available |  | n/a |
| Funding: |  |  |  |
|  25 | Sources of funding and other support (such as supply of drugs), role of funders |  | Included as statement |

**Extension of CONSORT for abstracts to reports of cluster randomised trials**

| **Item** | **Standard checklist item** | **Extension for cluster trials** | **Verification** |
| --- | --- | --- | --- |
| Title | Identification of study as randomised | Identification of study as cluster randomised | ✓ |
| Trial design | Description of the trial design (for example, parallel, cluster, non-inferiority) |  | ✓ |
| Methods: |  |  |  |
|  Participants | Eligibility criteria for participants and the settings where the data were collected | Eligibility criteria for clusters | ✓ |
|  Interventions | Interventions intended for each group |  | ✓ |
|  Objective | Specific objective or hypothesis | Whether objective or hypothesis pertains to the cluster level, the individual participant level, or both | ✓ |
|  Outcome | Clearly defined primary outcome for this report | Whether the primary outcome pertains to the cluster level, the individual participant level or both | ✓ |
|  Randomisation | How participants were allocated to interventions | How clusters were allocated to interventions | ✓ |
|  Blinding (masking) | Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment |  | ✓ |
| Results: |  |  |  |
|  Numbers randomised | Number of participants randomised to each group | Number of clusters randomised to each group | ✓ |
|  Recruitment | Trial status\* |  |  |
|  Numbers analysed | Number of participants analysed in each group | Number of clusters analysed in each group | ✓ |
|  Outcome | For the primary outcome, a result for each group and the estimated effect size and its precision | Results at the cluster or individual level as applicable for each primary outcome | ✓ |
|  Harms | Important adverse events or side effects |  | n/a |
| Conclusions | General interpretation of the results |  | ✓ |
| Trial registration | Registration number and name of trial register |  | ✓ |
| Funding | Source of funding |  | ✓ |

\*Relevant to conference abstracts.